Artwork

Content provided by Karen Jagoda. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karen Jagoda or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Skin Microbiome Targeted to Tackle Treatment-Resistant Dermatological Conditions with Venkat Nelabhotla Vyome Therapeutics

14:44
 
Share
 

Manage episode 237850783 series 99915
Content provided by Karen Jagoda. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karen Jagoda or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Venkat Nelabhotla, Chief Executive Officer, Vyome Therapeutics discusses the growing problem of antimicrobial resistance in medicine and how Vyome is working to tackle resistant dermatological conditions using their understanding of the skin microbiome. Focusing first on acne, Vyome is developing VB-1953, a topical gel capable of killing resistant strains of P. acnes to help deliver solutions to the more than 10 million patients in the US, and more world-wide, with antibiotic resistant acne.

@vyometx

Vyome Therapeutics

  continue reading

1733 episodes

Artwork
iconShare
 
Manage episode 237850783 series 99915
Content provided by Karen Jagoda. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karen Jagoda or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Venkat Nelabhotla, Chief Executive Officer, Vyome Therapeutics discusses the growing problem of antimicrobial resistance in medicine and how Vyome is working to tackle resistant dermatological conditions using their understanding of the skin microbiome. Focusing first on acne, Vyome is developing VB-1953, a topical gel capable of killing resistant strains of P. acnes to help deliver solutions to the more than 10 million patients in the US, and more world-wide, with antibiotic resistant acne.

@vyometx

Vyome Therapeutics

  continue reading

1733 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide